Emerging Therapeutic Approaches for Modulating the Intestinal Microbiota - PubMed
5 hours ago
- #dysbiosis
- #gut microbiota
- #therapeutic approaches
- The gut microbiota plays a vital role in metabolism, immunity, and disease susceptibility.
- Dysbiosis is linked to gastrointestinal disorders like IBS, IBD, and CDI, as well as extraintestinal conditions such as obesity and cardiovascular disease.
- Emerging therapeutic strategies include fecal microbiota transplantation (FMT), bacterial consortium transplantation (BCT), bacteriophage therapy, and outer membrane vesicles (OMVs).
- Probiotics, prebiotics, and synbiotics can remodel microbial communities, though their effectiveness varies by strain and context.
- FMT is effective for recurrent Clostridium difficile infections and is being explored for IBD, IBS, and other diseases.
- BCT provides a standardized alternative to donor-derived material, with FDA-approved products like SER-109 showing early success.
- Phage therapy and OMVs offer targeted microbial modulation and immune interactions but require more clinical data.
- These strategies hold promise for precision medicine but need further research for safety and standardization.